STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few

Exon-skipping drugs, a promising therapy for Duchenne muscular dystrophy, face challenges in accessibility, raising questions about the FDA's goal of encouraging treatments for rare diseases.